Xp11.2易位/TFE3基因融合相关肾细胞癌对mTOR抑制剂长期应答
本文报告一例44岁男性Xp11.2易位/TFE3基因融合相关肾细胞癌患者,在两次酪氨酸激酶抑制剂治疗失败后,接受依维莫司治疗并获得持续25个月的疾病缓解且无症状。作者认为mTOR抑制剂可作为此类患者的可选治疗线,并探讨了可能的作用机制。
要点
- Xp11.2/TFE3融合RCC年轻患者病程侵袭,但mTOR抑制剂可能有效。
- 本例依维莫司获25个月持续缓解且无症状。
- TKIs失败后mTOR抑制剂可作为治疗选择。
核心结论
- mTOR抑制剂可能是Xp11.2/TFE3基因融合相关RCC患者值得考虑的治疗选择。
研究设计与样本
- 个案报告:1例44岁男性Xp11.2易位/TFE3基因融合RCC患者,此前两次TKI治疗失败。
主要发现
- 患者接受依维莫司治疗后获得持续25个月的疾病缓解,且无症状。
关键数值与推荐
- 依维莫司治疗Xp11.2易位/TFE3基因融合RCC获得25个月持续缓解。
临床怎么用
- 对Xp11.2/TFE3基因融合RCC患者,尤其TKI治疗失败后,可考虑mTOR抑制剂如依维莫司。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To demonstrate that patients with Xp11.2/TFE3 gene-fusion translocation renal cell carcinoma (RCC), despite having an aggressive course in young adults, could have valid treatment options such as mammalian target of rapamycin (mTOR) inhibitors with good outcomes. Furthermore, to explain possible mechanisms of action of mTOR inhibitors in this type of RCC. MATERIALS AND METHODS: We report a case of a 44-year-old man who has been treated with everolimus for a Xp11.2 translocation/TFE3 gene-fusion RCC after 2 previous failed treatments with tyrosine kinase inhibitor. During the follow-up, we evaluated type and duration of response with everolimus. RESULTS: The patient obtained a long-lasting response of disease of 25 months with everolimus without any symptom. CONCLUSION: We believe that mTOR inhibitors could be a good line option treatment to consider for this type of patients.
引用
- Rua Fernández OR, Escala Cornejo R, Navarro Martín M, et al. Renal Cell Carcinoma Associated With Xp11.2 Translocation/TFE3 Gene-fusion: A Long Response to mammalian target of rapamycin (mTOR) Inhibitors. Urology. 2018. PMID: 29702156. doi:10.1016/j.urology.2018.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。